Review: Plasma exchange or intravenous immunoglobulin reduces disability in the Guillain-Barré syndrome

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p76
Academic Journal
This article presents a study, which states that in patients with the Guillain-Barr é syndrome (GBS), immunotherapy is consisting of plasma exchange, intravenous immunoglobulin (IgIV), or steroids are effective for reducing GBS-related disability. Studies were selected if they were randomized controlled trials (RCTs) that evaluated immunotherapy including plasma exchange, immunoabsorption, IgIV, or steroids in patients with GBS. 6 RCTs compared any form of corticosteroid or adrenocorticotrophic hormone with no steroid or placebo.


Related Articles

  • Review: Plasma exchange or intravenous immunoglobulin reduces disability in the Guillain-Barré syndrome: COMMENTARY. Bleck, Thomas P. // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p76 

    The value of treating patients with Guillain-Barr syndrome (GBS) with plasma exchange or intravenous immunoglobulin (IgIV) is beyond dispute. However, data from randomized clinical trials do not help a clinician choose between the agents for individual patients. This choice should consider the...

  • Guillain-Barré syndrome. Woodward, Sue // British Journal of Neuroscience Nursing;Apr/May2013, Vol. 9 Issue 2, p59 

    The article discusses the Guillain-Barre syndrome (GBS), a rare acute post-infective disorder that causes peripheral neuropathy and affects peripheral and cranial nerves. It mentions that the exact aetiology and pathophysiology of GBS are not known; symptoms include progressive ascending...

  • An uncommon cause of lower limb weakness. Berlot, G.; Viviani, M.; Bussani, R. // Intensive Care Medicine;Jan2000, Vol. 26 Issue 1, p128 

    We describe a case of a severely mentally disabled patient diagnosed as suffering from Guillain-Barré syndrome and treated with repeated plasma exchange. However, the abrupt onset of a cardiovascular collapse prompted a more in-depth diagnostic workup which demonstrated that the neurologic...

  • Adjunctive Steroid Therapy for Guillain-Barré Syndrome. Walling, Anne D. // American Family Physician;9/15/2004, Vol. 70 Issue 6, p1157 

    Discusses the study "Effect of Methylprednisolone When Added to Standard Treatment With Intravenous Immunoglobulin for Guillain-Barré Syndrome (GBS): Randomised Trial," by R. Van Koningsveld et al., published in the January 17, 2004 issue of the journal "The Lancet." Information on GBS;...

  • Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome. Hughes, Richard A. C. // Critical Care;2011, Vol. 15 Issue 4, p1 

    A new randomised controlled trial suggested that plasma exchange hastened removal from the ventilator in mechanically ventilated children with Guillain-Barré syndrome compared with intravenous immunoglobulin. Two larger trials in adults showed the opposite result.

  • Immunoglobulin.  // Reactions Weekly;4/1/2006, Issue 1095, p14 

    Presents a case report involving the use of immunoglobulin for polyradiculoneuritis. Reference to a study conducted by G. Vecchietti, K. Keri, C. Prins, G. Kaya, J-H. Saurat L. E. French published in the February 2006 issue of "Archives of Dermatology"; Association of the treatment with IV...

  • Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain—Barré syndromes. Kanzaki, M.; Kaida, K.; Ueda, M.; Morita, D.; Hirakawa, M.; Motoyoshi, K.; Kamakura, K.; Kusunoki, S. // Journal of Neurology, Neurosurgery & Psychiatry;Oct2008, Vol. 79 Issue 10, p1148 

    Background: Serum antibodies to GQ1b are associated with Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) with ophthalmoplegia. Antibodies to ganglioside complexes (GSCs) have not yet been examined in a large population of patients with MFS or GBS. This study aimed to determine...

  • Prospective study on anti-ganglioside antibodies in childhood Guillain—Barré syndrome. Schessi, J.; Koga, M.; Funakoshi, K.; Kirschner, J.; Mueliges, W.; Weishaupt, A.; Gold, R.; Korinthenberg, R. // Archives of Disease in Childhood;Jan2007, Vol. 92 Issue 1, p48 

    Background: Antiganglioside antibodies have been reported to play a part in the pathophysiology of Guillain-Barré syndrome (GBS). Aims: To investigate the prevalence and correlation of anti-ganglioside antibodies with clinical data in children with GBS in a multicentre clinical trial....

  • How is Guillain-Barré treated?  // Guillain-Barré Syndrome Fact Sheet;May2010, p4 

    The article presents information on the treatment of Guillain-Barré syndrome. There is no specific treatment available for this disease, however there are some therapies for accelerating the recovery and treating the complications of the disease. These therapies include plasma exchange (also...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics